Propanc Biopharma, Inc.

OTCPK:PPCB Stock Report

Market Cap: US$115.4k

Propanc Biopharma Valuation

Is PPCB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Unter dem Marktwert

  • Deutlich unter dem Marktwert

  • Price-To-Book gegen Gleichaltrige

  • Price-To-Book gegen Industrie

  • PM vs. Fair Ratio

  • Analysten-Prognose

Share Price vs Fair Value

What is the Fair Price of PPCB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von PPCB für die Bewertungsanalyse.

Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von PPCB für die Bewertungsanalyse.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for PPCB?

Other financial metrics that can be useful for relative valuation.

PPCB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-0.7x
PEG Ration/a

Price to Book Ratio vs Peers

How does PPCB's PB Ratio compare to its peers?

The above table shows the PB ratio for PPCB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average0.09x
ALNA.Q Allena Pharmaceuticals
0.03xn/aUS$109.9k
BLPH Bellerophon Therapeutics
0.2xn/aUS$672.8k
RGTP.Q RegenETP
0.06xn/aUS$718.6k
CAPS Capstone Holding
0.1xn/aUS$819.6k
PPCB Propanc Biopharma
n/an/aUS$115.4k

Price-To-Book gegen Gleichaltrige: PPCB hat ein negatives Eigenkapital und eine Price-To-Book Ratio (-0.1x) im Vergleich zum Durchschnitt der Vergleichsgruppe (0x).


Price to Earnings Ratio vs Industry

How does PPCB's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.8%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.8%
n/an/an/a
No more companies

Price-To-Book gegen Industrie: PPCB hat ein negatives Eigenkapital und eine Price-To-Book Ratio (-0.1x) im Vergleich zum US Biotechs Branchendurchschnitt (1.6x).


Price to Book Ratio vs Fair Ratio

What is PPCB's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PPCB PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-0.03x
Fair PB Ration/a

PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Book Fair Ratio von PPCB für die Bewertungsanalyse.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analysten-Prognose: Unzureichende Daten für eine Preisprognose.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.